Target intelligence / Profile preview

Proteinase-activated receptor 2 (PAR-2)

Target
PAR-2
Molecular classification
G protein-coupled receptor, Receptor
01

Overview

Proteinase-activated receptor 2 (PAR-2), encoded by the F2RL1 gene, is a class A G protein-coupled receptor (GPCR) that plays a critical role in inflammation, pain, and cancer. Unlike typical GPCRs that are activated by soluble ligands, PAR-2 is activated through proteolytic cleavage of its extracellular N-terminus by serine proteases such as trypsin, mast cell tryptase, and coagulation factors VIIa and Xa. This cleavage exposes a tethered ligand sequence (SLIGKV in humans) that binds intramolecularly to activate downstream G-protein (Gq/11, Gi, G12/13) and beta-arrestin signaling pathways. PAR-2 is widely expressed in epithelial cells, endothelial cells, immune cells, and neurons, where it modulates inflammatory responses, vascular tone, and nociception. In disease states, PAR-2 is frequently upregulated and contributes to chronic inflammatory conditions (such as atopic dermatitis, asthma, and inflammatory bowel disease), neuropathic and migraine pain, and tumor progression and metastasis in various cancers. Consequently, PAR-2 has emerged as a highly attractive therapeutic target, with several monoclonal antibodies (e.g., MEDI0618) and small-molecule negative allosteric modulators (e.g., DT-9046) undergoing clinical and preclinical evaluation to block its activation and alleviate inflammation and pain.

Other names
Coagulation factor II receptor-like 1Protease-activated receptor 2G-protein coupled receptor 11Thrombin receptor-like 1F2RL1GPR11PAR2
02

Mechanism of action

Antagonism (including negative allosteric modulation and monoclonal antibody blockade) to inhibit protease-mediated cleavage and subsequent activation of downstream G-protein and beta-arrestin signaling pathways; or agonism to stimulate these pathways.

03

Biological functions

Signal transductionImmune responseInflammatory responseCell migrationAngiogenesisNociceptionCell proliferation
04

Disease associations

InflammationCancerCardiovascular diseasePainAtopic dermatitisMigraineAsthmaInflammatory bowel diseaseKidney fibrosis
05

Safety considerations

Impaired tissue healing and barrier functionPotential cardiovascular side effects due to role in vascular homeostasisAltered immune response or immunosuppressionOff-target effects on other protease-activated receptors
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

PRO-PAR2 (PAR-2 activation neoepitope)F2RL1 expression levelsIL-6 levelsIL-8 levelsTSLP levels

Beyond the preview

Go deeper on Proteinase-activated receptor 2 (PAR-2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteinase-activated receptor 2 (PAR-2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call